Although today the diagnosis of AD has been developed into maturity with high accuracy, including molecular imaging approaches such as tau PET, amyloid PET, or 18F-FDG PET, no effective disease-modifying treatment is yet available (Wilson et al., 2019). The gene discussed is MAPT; the disease is Alzheimer disease.